Advertisement

Abbott Laboratories ABT

Set alert

Price alert · ABT

All alert types
110.16 USD +3.96 +3.73%

At close · Nov 2

110.44 +0.28 +0.25%

After hours · Nov 2, 7:29 PM ET

Bid
110.27 × 400
Ask
110.34 × 300
106.40 Day range 110.48
81.97 52-week range 132.03
YTD
-12.08%
1 year
-10.89%
Open
106.89
Prev close
106.20
Mkt cap
190.62B
Vol
8.85M
Avg vol
8.75M
EPS
2.69
P/E
40.95
Div yield
2.37%
More statistics
Low
106.40
High
110.48
Forward P/E
18.57
Beta
0.54
Short ratio
1.84
Inst. own
81.92%
Dividend
2.52
Ex-div date
Oct 14, 2026
Earnings
Jan 28, 2027
50-d avg
104.34
200-d avg
101.69
1y target
118.52

5Y chart

Chart tools
Interval

Events in this range
  • Jan 13, 2022Dividend: 0.47
  • Apr 13, 2022Dividend: 0.47
  • Jul 14, 2022Dividend: 0.47
  • Oct 13, 2022Dividend: 0.47
  • Jan 12, 2023Dividend: 0.51
  • Apr 13, 2023Dividend: 0.51
  • Jul 13, 2023Dividend: 0.51
  • Oct 12, 2023Dividend: 0.51
  • Oct 13, 2023Dividend: 0.51
  • Jan 11, 2024Dividend: 0.55
  • Jan 12, 2024Dividend: 0.55
  • Apr 12, 2024Dividend: 0.55
  • Jul 15, 2024Dividend: 0.55
  • Oct 15, 2024Dividend: 0.55
  • Jan 15, 2025Dividend: 0.59
  • Apr 15, 2025Dividend: 0.59
  • Jul 15, 2025Dividend: 0.59
  • Oct 15, 2025Dividend: 0.59
  • Oct 15, 2025Earnings: 1.3; estimate 1.3; surprise 0%
  • Jan 15, 2026Dividend: 0.63
  • Jan 22, 2026Earnings: 1.5; estimate 1.5; surprise 0%
  • Apr 15, 2026Dividend: 0.63
  • Apr 16, 2026Earnings: 1.15; estimate 1.14; surprise 0.88%
  • Jul 15, 2026Dividend: 0.63
  • Jul 16, 2026Earnings: 1.31; estimate 1.28; surprise 2.34%
  • Oct 15, 2026Dividend: 0.63
  • Oct 21, 2026Earnings: 1.42; estimate 1.42; surprise 0%
  • Oct 22, 2026Rating: JP Morgan · Overweight → Overweight
  • Oct 22, 2026Rating: Wells Fargo · Overweight → Overweight
  • Oct 22, 2026Rating: RBC Capital · Outperform → Outperform
  • Oct 22, 2026Rating: Citigroup · Buy → Buy
  • Oct 23, 2026Rating: Wells Fargo · Overweight → Overweight
  • Oct 27, 2026Downgrade: Argus Research · Buy → Hold
Signals (85)
NameDateAgo
SMA: BullishOct 26, 20261 week ago
SMA: BullishOct 5, 20264 weeks ago
SMA: BearishSep 28, 20261 month ago
SMA: BearishSep 7, 20261 month ago
SMA: BullishJul 20, 20263 months ago
SMA: BullishJun 22, 20264 months ago
MACD: Buy SignalJun 22, 20264 months ago
RSI: OversoldMar 30, 20267 months ago
RSI: OversoldJan 19, 20269 months ago
SMA: BearishOct 13, 20251 year ago
SMA: BearishOct 6, 20251 year ago
SMA: BullishAug 4, 20251 year ago
SMA: BullishAug 4, 20251 year ago
SMA: BearishJul 14, 20251 year ago
SMA: BearishJul 7, 20251 year ago
MACD: Sell SignalMay 19, 20251 year ago
MACD: Buy SignalMay 12, 20251 year ago
SMA: BullishApr 28, 20251 year ago
SMA: BearishApr 21, 20251 year ago
SMA: BullishApr 14, 20251 year ago
SMA: BearishMar 31, 20251 year ago
MACD: Sell SignalMar 31, 20251 year ago
SMA: BullishMar 24, 20251 year ago
SMA: BearishMar 10, 20251 year ago
RSI: OverboughtFeb 10, 20251 year ago
SMA: BullishJan 20, 20251 year ago
MACD: Buy SignalJan 20, 20251 year ago
SMA: BullishJan 13, 20251 year ago
SMA: BearishJan 6, 20251 year ago
MACD: Sell SignalDec 9, 20241 year ago
SMA: BearishDec 2, 20241 year ago
SMA: BullishOct 28, 20242 years ago
SMA: BearishOct 21, 20242 years ago
SMA: BullishAug 12, 20242 years ago
SMA: BearishAug 5, 20242 years ago
SMA: BullishJul 29, 20242 years ago
MACD: Buy SignalJul 29, 20242 years ago
SMA: BullishJul 22, 20242 years ago
SMA: BearishJun 24, 20242 years ago
SMA: BullishJun 17, 20242 years ago
SMA: BearishJun 10, 20242 years ago
SMA: BullishJun 3, 20242 years ago
SMA: BearishApr 22, 20242 years ago
MACD: Sell SignalApr 1, 20242 years ago
SMA: BearishMar 18, 20242 years ago
SMA: BullishNov 27, 20232 years ago
MACD: Buy SignalNov 20, 20232 years ago
SMA: BullishNov 13, 20232 years ago
MACD: Sell SignalAug 14, 20233 years ago
SMA: BearishAug 7, 20233 years ago
SMA: BearishJul 31, 20233 years ago
SMA: BullishJul 10, 20233 years ago
SMA: BullishJul 10, 20233 years ago
SMA: BearishJul 3, 20233 years ago
SMA: BearishJul 3, 20233 years ago
SMA: BullishJun 19, 20233 years ago
SMA: BullishJun 19, 20233 years ago
MACD: Buy SignalJun 19, 20233 years ago
MACD: Sell SignalJun 5, 20233 years ago
SMA: BearishMay 22, 20233 years ago
SMA: BearishMay 22, 20233 years ago
SMA: BullishApr 17, 20233 years ago
MACD: Buy SignalApr 17, 20233 years ago
SMA: BearishApr 10, 20233 years ago
SMA: BullishApr 3, 20233 years ago
SMA: BullishApr 3, 20233 years ago
SMA: BearishFeb 20, 20233 years ago
MACD: Sell SignalFeb 20, 20233 years ago
SMA: BearishFeb 6, 20233 years ago
SMA: BullishNov 21, 20223 years ago
SMA: BullishNov 7, 20223 years ago
MACD: Buy SignalNov 7, 20223 years ago
MACD: Sell SignalSep 26, 20224 years ago
SMA: BearishSep 12, 20224 years ago
SMA: BullishSep 5, 20224 years ago
SMA: BearishAug 22, 20224 years ago
SMA: BullishAug 8, 20224 years ago
MACD: Buy SignalJun 27, 20224 years ago
SMA: BearishJun 6, 20224 years ago
SMA: BullishMay 23, 20224 years ago
SMA: BearishApr 25, 20224 years ago
SMA: BullishApr 18, 20224 years ago
SMA: BearishApr 11, 20224 years ago
SMA: BullishApr 4, 20224 years ago
SMA: BearishJan 10, 20224 years ago

Key statistics

Market cap
192.07B
Enterprise value
211.54B
Trailing P/E
40.99
Forward P/E
18.57
PEG ratio
1.52
Price / sales
3.98
Price / book
3.73
EPS (TTM)
2.69
Beta
0.54
Dividend yield
2.37%
Payout ratio
78.71%
Profit margin
9.75%
Revenue (TTM)
48.23B
Revenue growth
14.50%
Free cash flow
0
Total cash
5.60B
Total debt
32.72B
Return on equity
0.00%
Shares outstanding
1.74B
Short % of float
1.12%
50-day average
104.34
200-day average
101.69

Analyst view

Consensus: buy

Buy
Price target (mean) 118.52 +7.6% upside
Target (low)
100.00
Target (mean)
118.52
Target (high)
130.00
Ratings (0m) 28 23 buy · 5 hold · 0 sell
  • Strong buy5
  • Buy18
  • Hold5
  • Sell0
  • Strong sell0

Next earnings

Jan 28, 2027

Expected Jan 28, 2027. Consensus EPS estimate 1.64.

Earnings history

Financials — quick view

All financials
ABT Revenue — quarterly 12.59B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ABT Net income — quarterly 928.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ABT EPS — quarterly 0.53
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ABT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 28, 2027Dec 30, 20261.64———
Oct 21, 2026Sep 30, 20261.421.420.000.00%
Jul 16, 2026Jun 30, 20261.281.31+0.03+2.34%
Apr 16, 2026Mar 31, 20261.141.15+0.01+0.88%
Jan 22, 2026Dec 31, 20251.501.500.000.00%
Oct 15, 2025Sep 30, 20251.301.300.000.00%

Upgrades / downgrades

ABT analyst upgrades and downgrades
DateFirmActionFromTo
Oct 27, 2026Argus ResearchdownBuyHold
Oct 23, 2026Wells FargomainOverweightOverweight
Oct 22, 2026CitigroupmainBuyBuy
Oct 22, 2026RBC CapitalmainOutperformOutperform
Oct 22, 2026Wells FargomainOverweightOverweight
Oct 22, 2026JP MorganmainOverweightOverweight

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
abbott.com

News

Your note

Sign in to keep a note on ABT — it syncs with the Stock Master app.

Insider holders

ABT insider holders
InsiderRelationLatest transactionDateShares held
ALLEN HUBERT L.OfficerStock Award(Grant)Feb 24, 2025200,281
BOUDREAU PHILIP PChief Financial OfficerPurchaseApr 22, 20260
CONROY KEVIN TDirectorStock Award(Grant)Apr 23, 2026133,737
EARNHARDT LISA DOfficerStock Award(Grant)Feb 23, 202698,984
FORD ROBERT B.Chief Executive OfficerSaleAug 24, 2026522,664
MORELAND MARY KOfficerSaleMar 1, 2026116,136

Institution ownership

ABT institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.82%152,563,47616.82BJun 29, 2026
Vanguard Capital Management LLC6.57%113,750,99412.54BJun 29, 2026
State Street Corporation4.68%80,926,2348.92BJun 29, 2026
Charles Schwab Investment Management, Inc.3.45%59,674,5076.58BJun 29, 2026
Vanguard Portfolio Management LLC2.83%49,017,8665.41BJun 29, 2026
Geode Capital Management, LLC2.27%39,219,3374.32BJun 29, 2026

Fund ownership

ABT fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.20%55,297,2796.10BJun 29, 2026
SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF2.75%47,631,7455.25BAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.61%45,138,4904.98BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%23,056,9072.54BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.31%22,610,2902.49BAug 30, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%21,408,9182.36BSep 29, 2026
Advertisement